AACR Honors Bert Vogelstein, M.D., with Distinguished Lectureship
CHICAGO — The American Association for Cancer Research will award Bert Vogelstein, M.D., with the Eighth Annual AACR-Irving Weinstein Foundation Distinguished Lectureship at the AACR Annual Meeting 2012, held here March 31 – April 4.
Vogelstein’s lecture, “Cancer genomics and their implications for research and patients,” will take place on Monday, April 2 at 3:30 p.m. CT in the Skyline Ballroom of McCormick Place.
“We congratulate Dr. Vogelstein on his paradigm-shifting research in the application of molecular biology to the study of human cancer,” said Margaret Foti, Ph.D., M.D. (h.c.), chief executive officer of the AACR. “His landmark contributions have stimulated new thinking about cancer science and its potential clinical impact.”
The AACR-Irving Weinstein Foundation Distinguished Lectureship was established in 2004 to acknowledge an individual whose outstanding innovations in science and whose position as a thought leader have the potential to inspire creative thinking and new directions in cancer research.
“When Judy Garber invited me to give this award, she said that its major purpose was to ‘inspire young investigators toward creative avenues of research.’ That purpose resonated with me, as young investigators, particularly students and post-docs, have been responsible for virtually all of the advances in cancer research, and our future is in their hands,” said Vogelstein, director of the Ludwig Center for Cancer Genetics and Therapeutics, professor of oncology and pathology and an investigator at the Howard Hughes Medical Institute at the Sidney Kimmel Comprehensive Cancer Center of the Johns Hopkins University School of Medicine.
“This lecture will give me a chance to highlight the work of the young investigators in my laboratory, and to emphasize how many opportunities there are for creative uses of the information gained from cancer genetics in the immediate future,” he added.
Vogelstein’s scientific expertise is in determining the molecular and genetic causes of cancer. In the late 1980’s, he formulated a model for the development of colorectal tumors that has formed the conceptual basis for understanding solid tumors in general. Since that time, he has devoted his career to identifying the genes and mutations predicted by his model. In the process, he, together with long-time collaborator Kenneth W. Kinzler, Ph.D., and their team, have discovered many of the genetic alterations that underlie numerous forms of human cancers, including those in such well-known genes as p53, APC, b-catenin, PIK3CA, and IDH1.
Currently, Vogelstein’s research team is interested in engineering novel ways to diagnose cancer as well as an individual’s degree of susceptibility toward developing cancer based on his or her genetics. Such techniques would allow for early detection of potentially oncogenic mutations through routine blood tests.
Vogelstein obtained his medical degree from Johns Hopkins University School of Medicine, where he also completed his internship and residency in pediatrics. During his postdoctoral fellowship at the National Cancer Institute, he focused his research on new techniques in molecular biology.
He has been honored with numerous awards including, but not limited to, the Young Investigator Award from the American Federation for Clinical Research, The Gairdner Foundation International Award in Science, the Pezcoller Foundation AACR-International Award for Cancer Research, the Richard Lounsbery Award from the National Academy of Sciences and the AACR G.H.A. Clowes Memorial Award. Vogelstein is also a member of the National Academy of Sciences, the Institute of Medicine, the American Academy of Arts and Sciences, the American Philosophical Society and the European Molecular Biology Organization.
Press registration for the AACR Annual Meeting 2012 is free to qualified journalists and public information officers: www.aacr.org/PressRegistration.
About the AACR
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR’s membership includes 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 18,000 attendees. In addition, the AACR publishes seven peer-reviewed scientific journals and a magazine for cancer survivors, patients and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of individual and team science grants in cancer research that have the potential for patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer.
For more information about the AACR, visit www.AACR.org.
In Chicago, March 31 – April 4: